Politics and Government Politics and Government
Wed, November 27, 2024
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ] - Brian Stokes
Trust Matters in Cabinet Picks
Mon, November 25, 2024
Sun, November 24, 2024
Thu, November 14, 2024
Tue, November 12, 2024
Thu, April 23, 2009
Mon, February 2, 2009
[ Mon, Feb 02nd 2009 ] - Nathan Burkes
Is Obama a rock star?
Fri, January 30, 2009

Inhibitex to Host Conference Call to Report Third Quarter Financial Results on November 9, 2010


//health-fitness.news-articles.net/content/2010/ .. uarter-financial-results-on-november-9-2010.html
Published in Health and Fitness on Friday, October 29th 2010 at 12:35 GMT by Market Wire   Print publication without navigation


ATLANTA--([ BUSINESS WIRE ])--Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Tuesday, November 9, 2010 at 9:00 a.m. EST to review the Companya™s third quarter financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call.

Webcast Information

To access the conference call, please dial (877) 407-9210 (domestic) or (201) 689-8049 (international). A replay of the call will be available from 11:00 a.m. Eastern Standard Time on November 9th until December 10, 2010 at midnight. To access the replay, please dial (877) 660-6853 (domestic) or (201) 612-7415 (international) and reference the account # 286 and the conference id # 359917. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at [ http://www.inhibitex.com ].

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Companya™s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1 clinical development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines.

For additional information about the Company, please visit [ www.inhibitex.com ].


Publication Contributing Sources